文献速递乳腺癌

曲妥珠单抗瑞泽替康对比吡咯替尼联合卡培他滨治疗HER2阳性转移性乳腺癌:HORIZON-Breast01期中分析

Trastuzumab rezetecan versus pyrotinib plus capecitabine for patients with HER2-positive metastatic breast cancer (HORIZON-Breast01): interim analysis of a multicentre, open-label, randomised, controlled, phase 3 trial.
PubMed 文献 · Lancet Oncol · 2026-07-01

BACKGROUND: Trastuzumab rezetecan has shown antitumour activity in a phase 1 trial. Pyrotinib plus capecitabine is the current standard treatment for patients with HER2-positive advanced or metastatic breast cancer after trastuzumab and chemotherapy (taxane or anthracycline).…

要点

  • 曲妥珠单抗瑞泽替康组≥3级中性粒细胞减少发生率为54%,间质性肺病发生率为3%。

核心结论

  • 曲妥珠单抗瑞泽替康相比吡咯替尼联合卡培他滨显著改善了HER2阳性转移性乳腺癌患者的无进展生存期,并显示出不同的安全性特征,可能成为新的治疗选择。

研究设计与样本

  • 多中心、开放标签、随机对照3期试验的期中分析,在中国50家医院开展,共随机分配287例HER2阳性转移性乳腺癌患者(曲妥珠单抗瑞泽替康组142例,对照组145例),按1:1比例随机,并根据激素受体状态和既往转移性化疗线数分层。

主要发现

  • 最常见的≥3级治疗相关不良事件为中性粒细胞计数减少(曲妥珠单抗瑞泽替康组54% vs 对照组9%)、白细胞计数减少(20% vs 3%)和血小板计数减少(11% vs 1%)。
  • 治疗相关严重不良事件发生率分别为13%(19例)和12%(17例);曲妥珠单抗瑞泽替康组间质性肺病发生率为3%(4例)。

关键数值与推荐

  • 入组标准:年龄18-75岁,组织学确诊HER2阳性不可切除或转移性乳腺癌,既往晚期阶段接受过紫杉类和曲妥珠单抗治疗,或(新)辅助抗HER2单克隆抗体联合紫杉类方案治疗后12个月内疾病进展,具有可测量病灶,ECOG体能状态评分0或1。

临床怎么用

  • 对于既往接受过曲妥珠单抗和紫杉类治疗的HER2阳性转移性乳腺癌患者,曲妥珠单抗瑞泽替康可作为潜在的新的治疗选择,但需密切监测中性粒细胞减少等血液学毒性及间质性肺病。

局限性

  • 研究为开放标签设计,可能引入偏倚;试验仅在中国进行,人群以汉族为主(93%),结果外推需谨慎。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Trastuzumab rezetecan has shown antitumour activity in a phase 1 trial. Pyrotinib plus capecitabine is the current standard treatment for patients with HER2-positive advanced or metastatic breast cancer after trastuzumab and chemotherapy (taxane or anthracycline). We aimed to evaluate the efficacy and safety of trastuzumab rezetecan versus pyrotinib plus capecitabine in this patient population. METHODS: This interim analysis of a multicentre, open-label, randomised, controlled, phase 3 trial was conducted at 50 hospitals in China. Eligible patients were aged 18-75 years with histologically confirmed HER2-positive unresectable or metastatic breast cancer; previously received a taxane and trastuzumab at the advanced stage or had disease progression within 12 months after (neo)adjuvant treatment with an anti-HER2 monoclonal antibody and taxane-based regimen; had measurable lesions; and an Eastern Cooperative Oncology Group performance status of 0 or 1. Patients were randomly assigned (1:1; stratified by hormone receptor status and previous lines of chemotherapy for metastatic disease), using permuted blocks to intravenous trastuzumab rezetecan (4·8 mg/kg) on day 1 of each 21-day cycle or oral pyrotinib 400 mg once per day continuously plus oral capecitabine 1000 mg/m2 twice per day on days 1-14 of each 21-day cycle. Protocol amendments led to a temporary modification (between Nov 29, 2022, and July 12, 2023) of trastuzumab rezetecan dose to 6·4 mg/kg; primary evaluation focuses on the 4·8 mg/kg group. The primary endpoint was progression-free survival per blinded independent central review in the modified intention-to-treat population 1 (defined as all patients randomly assigned to the trastuzumab rezetecan 4·8 mg/kg or control groups). Results presented here are from a prespecified interim analysis. This study was registered with ClinicalTrials.gov, NCT05424835 (active, not recruiting). FINDINGS: From Aug 4, 2022, to Aug 9, 2024, 414 patients with HER2-positive metastatic breast cancer were assessed for eligibility, 127 were ineligible and 287 were randomly assigned to trastuzumab rezetecan (n=142) or pyrotinib plus capecitabine (control group; n=145) in the modified intention-to-treat population 1. All 287 patients were female and the median age was 55·0 years (IQR 49·0-60·0). 268 (93%) patients self-reported as Han Chinese and 19 (7%) as other Chinese ethnicity. At data cutoff of the interim analysis on June 30, 2025, after a median follow-up of 15·0 months (IQR 12·9-18·5) for the trastuzumab rezetecan group versus 13·9 months (11·4-17·8) for the control group, 124 progression-free survival events had occurred (37 [26%] vs 87 [60%]). The median progression-free survival was 30·6 months (95% CI 16·8-not reached [NR]) with trastuzumab rezetecan and 8·3 months (6·9-11·0) with pyrotinib plus capecitabine (HR 0·22 [0·15-0·34]; p<0·0001). The 12-month progression-free survival rate was 84·7% (77·0-90·0) in the trastuzumab rezetecan group versus 35·5% (26·8-44·2) in the control group. The most common (grade ≥3) treatment-related adverse events were decreased neutrophil count (77 [54%] with trastuzumab rezetecan vs 13 [9%] with the control), decreased white blood cell count (29 [20%] vs four [3%]), and decreased platelet count (15 [11%] vs two [1%]); whereas treatment-related serious adverse events occurred in 19 (13%) versus 17 (12%). Two adverse events led to death (one [1%] septic shock unrelated to trastuzumab rezetecan treatment and one [1%] unknown reason related to pyrotinib plus capecitabine treatment). Interstitial lung disease occurred in four (3%) patients in the trastuzumab rezetecan group. INTERPRETATION: Trastuzumab rezetecan improved progression-free survival versus pyrotinib plus capecitabine and showed a distinct safety profile in patients with HER2-positive breast cancer, presenting as a potential new treatment option. FUNDING: Jiangsu Hengrui Pharmaceuticals. TRANSLATION: For the Chinese translation of the abstract see Supplementary Materials section.

来源:Lancet Oncol,查看原文。版权归原作者所有。

引用

  1. Yao H, Zhang Q, Li H, et al. Trastuzumab rezetecan versus pyrotinib plus capecitabine for patients with HER2-positive metastatic breast cancer (HORIZON-Breast01): interim analysis of a multicentre, open-label, randomised, controlled, phase 3 trial. Lancet Oncol. 2026. PMID: 42385760. doi:10.1016/S1470-2045(26)00193-2

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。